Measles virus-vaccine infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells

Archive ouverte

Guillerme, Jean-Baptiste | Boisgerault, Nicolas | Roulois, David | Ménager, Jérémie | Combredet, Chantal | Tangy, Frédéric | Fonteneau, Jean-François | Gregoire, Marc

Edité par CCSD ; American Association for Cancer Research -

International audience. Purpose: Plasmacytoid dendritic cells (pDC) are antigen-presenting cells specialized in antiviral response. The measles virus vaccine (MV) is proposed as an antitumor agent to target and specifically kill tumor cells without infecting healthy cells. Experimental design: Here, we investigated, in vitro, the effects of MV-infected tumor cells on phenotype and functions of human pDC. We studied maturation and tumor antigen cross-presentation by pDC, exposed either to the virus alone, or to MV-infected or UV-irradiated tumor cells. Results: We found that only MV-infected cells induced pDC maturation with a strong production of IFN-α, whereas UV-irradiated tumor cells were unable to activate pDC. This IFN-α production was triggered by the interaction of MV ssRNA with TLR7. We observed that MV-infected tumor cells were phagocytosed by pDC. Interestingly, we showed cross-presentation of the tumor antigen, NYESO-1, to a specific CD8+ T-cell clone, when pDC were cocultured with MV-infected tumor cells, whereas pDC were unable to cross-present NYESO-1 after coculture with UV-irradiated tumor cells. Conclusions: Altogether, our results suggest that the use of MV in antitumor virotherapy induces immunogenic tumor cell death, allowing pDC to mature, produce high amounts of IFN-α, and cross-present tumor antigen, thus representing a mode of recruiting these antigen presenting cells in the immune response.

Suggestions

Du même auteur

Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells

Archive ouverte | Achard, Carole | CCSD

International audience. Attenuated measles virus (MV) is currently being evaluated in clinical trials as an oncolytic therapeutic agent. Originally used for its lytic activity against tumor cells, it is now admitted...

Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells

Archive ouverte | Fonteneau, Jean-François | CCSD

International audience. Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to a...

Monitoring antigen cross-presentation by human dendritic cells purified from peripheral blood

Archive ouverte | Isnard, Stephane | CCSD

International audience

Chargement des enrichissements...